ライフサイエンスコーパス: obstructive jaundice

1 , 41 to 89 years; mean age, 66.9 years) with obstructive jaundice.

2 acement is an effective method of palliating obstructive jaundice.

3 provides temporary relief for patients with obstructive jaundice.

4 sis, and alleviates kidney injury induced by obstructive jaundice.

5 d from 50 patients with clinically suspected obstructive jaundice.

6 Obstructive jaundice (46.5%) was the most common MRCP in

7 body from esophagus (87.50%), management of obstructive jaundice (72.50%) and biliary pancreatitis (

8 (mean age, 62 y) men (85%), presenting with obstructive jaundice (77%) associated with autoimmune pa

9 diverticulum (JPDD) has been associated with obstructive jaundice and ascending cholangitis.

10 h IgG4-associated cholangitis presented with obstructive jaundice and had increased serum IgG4 levels

11 th cholelithiasis, often in association with obstructive jaundice and pancreatitis.

12 creatic abnormalities in most patients, with obstructive jaundice being the primary indication and ob

13 Preoperative obstructive jaundice considerably increases perioperativ

14 Although rare, obstructive jaundice due to external bile duct compressi

15 Obstructive jaundice from pancreatobiliary diseases repr

16 Using Fischer's formula, 158 patients with obstructive jaundice from pancreatobiliary diseases were

17 insights into the management and outcomes of obstructive jaundice from pancreatobiliary diseases.

18 Although obstructive jaundice has been associated with a predispo

19 inoma, liver surgery, liver transplantation, obstructive jaundice, hepatitis C antiviral treatment) d

20 ledochal cysts (CDC) are important causes of obstructive jaundice in pediatric patients.

21 In this study of 158 patients with obstructive jaundice in Rwanda, ERCP was the predominant

22 rns, therapeutic approaches, and outcomes of obstructive jaundice in the Rwandan healthcare context.

23 nted to an outside hospital with symptoms of obstructive jaundice, including abdominal pain and yello

24 However, its role in obstructive jaundice-induced kidney injury remains unexp

25 Obstructive jaundice is an uncommon presentation for pat

26 Obstructive jaundice is associated with immunologic dera

27 with IAC present with biliary strictures and obstructive jaundice, making cholangiocarcinoma (CCA) an

28 (n = 22), autoimmune hepatitis (n = 10), and obstructive jaundice (n = 12).

29 recorded after stent implantation and until obstructive jaundice occurred.

30 Obstructive jaundice (OJ)-induced kidney injury has a hi

31 HPLC can quantify GCDC acid serum on obstructive jaundice patients and can be used to support

32 aimed to quantify the serum level of GCDC in obstructive jaundice patients.

33 at when injected into newborn mice causes an obstructive jaundice phenotype with lower mortality rate

34 resented, including antifibrinolytic agents, obstructive jaundice, prostaglandin inhibitors, cyclospo

35 Thus, obstructive jaundice selectively expands liver myeloid D

36 ore frequently in patients with preoperative obstructive jaundice than in those without jaundice.

37 The major cause for obstructive jaundice was choledocholithiasis.

38 le with an unusual clinical manifestation of obstructive jaundice (which has not been reported so far

39 The patient was found to have obstructive jaundice with multiple mass lesions in the l

40 has excellent accuracy in the evaluation of obstructive jaundice with regards to the level and cause

41 nd out the role of MDCT in the evaluation of obstructive jaundice with respect to the cause and level